vs
Apellis Pharmaceuticals, Inc.（APLS）与WSFS FINANCIAL CORP（WSFS）财务数据对比。点击上方公司名可切换其他公司
WSFS FINANCIAL CORP的季度营收约是Apellis Pharmaceuticals, Inc.的1.4倍（$275.3M vs $199.9M），WSFS FINANCIAL CORP净利率更高（31.5% vs -29.5%，领先61.0%），WSFS FINANCIAL CORP同比增速更快（7.5% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 1.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
WSFS金融集团是一家金融服务企业，核心子公司WSFS银行是总部位于特拉华州及大特拉华谷地区规模最大、经营历史最久的本地管理银行与财富管理机构。集团共运营115个网点，其中88个为银行网点，分布在宾夕法尼亚、特拉华、新泽西、佛罗里达、弗吉尼亚、内华达六州，提供全面金融服务。
APLS vs WSFS — 直观对比
营收规模更大
WSFS
是对方的1.4倍
$199.9M
营收增速更快
WSFS
高出13.4%
-5.9%
净利率更高
WSFS
高出61.0%
-29.5%
两年增速更快
APLS
近两年复合增速
1.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $275.3M |
| 净利润 | $-59.0M | $86.8M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | 31.5% |
| 营收同比 | -5.9% | 7.5% |
| 净利润同比 | -62.2% | 31.7% |
| 每股收益（稀释后） | $-0.40 | $1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSWSFS
| Q1 26 | — | $275.3M | ||
| Q4 25 | $199.9M | $271.9M | ||
| Q3 25 | $458.6M | $270.5M | ||
| Q2 25 | $178.5M | $267.5M | ||
| Q1 25 | $166.8M | $256.1M | ||
| Q4 24 | $212.5M | $261.5M | ||
| Q3 24 | $196.8M | $267.7M | ||
| Q2 24 | $199.7M | $266.0M |
净利润APLSWSFS
| Q1 26 | — | $86.8M | ||
| Q4 25 | $-59.0M | $72.7M | ||
| Q3 25 | $215.7M | $76.4M | ||
| Q2 25 | $-42.2M | $72.3M | ||
| Q1 25 | $-92.2M | $65.9M | ||
| Q4 24 | $-36.4M | $64.2M | ||
| Q3 24 | $-57.4M | $64.4M | ||
| Q2 24 | $-37.7M | $69.3M |
营业利润率APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | 35.8% | ||
| Q3 25 | 48.7% | 37.3% | ||
| Q2 25 | -18.6% | 35.7% | ||
| Q1 25 | -50.0% | 34.0% | ||
| Q4 24 | -12.3% | 32.3% | ||
| Q3 24 | -24.0% | 31.9% | ||
| Q2 24 | -14.7% | 34.0% |
净利率APLSWSFS
| Q1 26 | — | 31.5% | ||
| Q4 25 | -29.5% | 26.7% | ||
| Q3 25 | 47.0% | 28.3% | ||
| Q2 25 | -23.6% | 27.0% | ||
| Q1 25 | -55.3% | 25.7% | ||
| Q4 24 | -17.1% | 24.6% | ||
| Q3 24 | -29.2% | 24.1% | ||
| Q2 24 | -18.9% | 26.0% |
每股收益（稀释后）APLSWSFS
| Q1 26 | — | $1.64 | ||
| Q4 25 | $-0.40 | $1.33 | ||
| Q3 25 | $1.67 | $1.37 | ||
| Q2 25 | $-0.33 | $1.27 | ||
| Q1 25 | $-0.74 | $1.12 | ||
| Q4 24 | $-0.30 | $1.08 | ||
| Q3 24 | $-0.46 | $1.08 | ||
| Q2 24 | $-0.30 | $1.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $2.7B |
| 总资产 | $1.1B | $22.1B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $1.7B | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | $1.2B | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | — |
股东权益APLSWSFS
| Q1 26 | — | $2.7B | ||
| Q4 25 | $370.1M | $2.7B | ||
| Q3 25 | $401.2M | $2.8B | ||
| Q2 25 | $156.3M | $2.7B | ||
| Q1 25 | $164.2M | $2.7B | ||
| Q4 24 | $228.5M | $2.6B | ||
| Q3 24 | $237.1M | $2.7B | ||
| Q2 24 | $264.3M | $2.5B |
总资产APLSWSFS
| Q1 26 | — | $22.1B | ||
| Q4 25 | $1.1B | $21.3B | ||
| Q3 25 | $1.1B | $20.8B | ||
| Q2 25 | $821.4M | $20.8B | ||
| Q1 25 | $807.3M | $20.5B | ||
| Q4 24 | $885.1M | $20.8B | ||
| Q3 24 | $901.9M | $20.9B | ||
| Q2 24 | $904.5M | $20.7B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $220.0M | ||
| Q3 25 | $108.5M | $121.5M | ||
| Q2 25 | $4.4M | $37.2M | ||
| Q1 25 | $-53.4M | $8.7M | ||
| Q4 24 | $19.4M | $219.9M | ||
| Q3 24 | $34.1M | $3.1M | ||
| Q2 24 | $-8.3M | $44.8M |
自由现金流APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $213.6M | ||
| Q3 25 | $108.3M | $120.3M | ||
| Q2 25 | $4.4M | $35.2M | ||
| Q1 25 | $-53.4M | $6.3M | ||
| Q4 24 | $19.3M | $205.6M | ||
| Q3 24 | — | $-489.0K | ||
| Q2 24 | $-8.4M | $42.1M |
自由现金流率APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 78.6% | ||
| Q3 25 | 23.6% | 44.5% | ||
| Q2 25 | 2.5% | 13.2% | ||
| Q1 25 | -32.0% | 2.5% | ||
| Q4 24 | 9.1% | 78.6% | ||
| Q3 24 | — | -0.2% | ||
| Q2 24 | -4.2% | 15.8% |
资本支出强度APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 2.3% | ||
| Q3 25 | 0.0% | 0.5% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.9% | ||
| Q4 24 | 0.0% | 5.5% | ||
| Q3 24 | 0.0% | 1.4% | ||
| Q2 24 | 0.0% | 1.0% |
现金转化率APLSWSFS
| Q1 26 | — | — | ||
| Q4 25 | — | 3.03× | ||
| Q3 25 | 0.50× | 1.59× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 0.13× | ||
| Q4 24 | — | 3.43× | ||
| Q3 24 | — | 0.05× | ||
| Q2 24 | — | 0.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
WSFS
暂无分部数据
